Focal nodular hyperplasia (FNH) is a benign liver growth that develops when liver cells multiply in response to an abnormal blood vessel nearby. It is the second most common benign liver tumor, and it carries virtually no risk of turning into cancer. Most people with FNH never experience symptoms and discover the lesion incidentally during imaging for something else entirely.
Why FNH Develops
FNH is not a true tumor in the way most people think of one. Instead, it forms as a reaction to a vascular abnormality already present in the liver, such as a malformed artery or an abnormal connection between arteries and veins. That vascular quirk disrupts normal blood flow in a small area, creating zones of either too much or too little oxygen. The surrounding liver cells respond by growing larger and multiplying to compensate, essentially overbuilding the tissue around the problem vessel.
This process also activates specialized cells in the liver called stellate cells, which lay down scar tissue in the center of the growing mass. That central scar is one of FNH’s signature features and helps doctors identify it on imaging. The abnormal artery itself thickens and branches outward through the lesion like the spokes of a wheel, feeding blood to the overgrown tissue. Because the entire process is a reactive, self-limiting response rather than uncontrolled cell division, FNH stays benign.
Who Gets FNH
FNH disproportionately affects women, at a ratio of roughly 8 to 1 compared with men. It is most commonly found in women between ages 20 and 50, which has led researchers to suspect a link with estrogen. That said, oral contraceptives have not been proven to cause FNH. Women who take daily estrogen-based contraceptives do tend to have larger nodules than women who don’t, and women in general have larger nodules than men, regardless of contraceptive use.
The distinction matters because almost all documented cases of FNH hemorrhage or rupture, both extremely rare events, have occurred in patients taking oral contraceptives. For that reason, some doctors recommend stopping estrogen-based contraception if a lesion is found, particularly a large one. Obesity also increases the body’s overall estrogen load and may play a similar role in nodule growth.
Symptoms and How FNH Is Found
The vast majority of people with FNH have no symptoms at all. When symptoms do occur, they typically involve a vague sense of fullness or mild discomfort in the upper right abdomen, sometimes from a larger lesion pressing on surrounding tissue. Occasionally a large FNH can be felt during a physical exam, but this is uncommon. Most lesions are discovered by accident when a person undergoes an abdominal ultrasound, CT scan, or MRI for an unrelated reason.
How Doctors Confirm the Diagnosis
Imaging is the primary tool for diagnosing FNH, and experienced centers can make an accurate diagnosis through imaging alone in about 90% of cases. Contrast-enhanced ultrasound is often the first choice. The lesion lights up rapidly and evenly when contrast dye is injected, reflecting its rich blood supply from that central abnormal artery.
MRI provides the most detailed picture. On a standard MRI, FNH appears nearly identical to normal liver tissue, except for the central scar, which shows up as a bright spot on certain sequences. A specialized contrast agent that is taken up by functioning liver cells makes the diagnosis even more reliable. Because FNH contains working hepatocytes (unlike most other liver masses), the lesion retains this contrast in later imaging phases and appears bright. Using this technique, sensitivity for correctly identifying FNH reaches about 96%.
If imaging remains uncertain, a tissue sample examined under a microscope can settle the question. FNH has two hallmark features on biopsy: the liver cells look normal (not cancerous), and the lesion contains abnormal portal tracts, the small bundles of vessels and bile ducts found throughout a healthy liver. A particular staining technique highlights a protein called glutamine synthetase, which in FNH forms a distinctive “map-like” pattern of broad, interconnected zones. This pattern is unique to FNH and helps pathologists distinguish it from other lesions with high confidence.
FNH vs. Hepatic Adenoma
The lesion most commonly confused with FNH is a hepatic adenoma. The distinction is important because adenomas carry real risks: clinically significant bleeding occurs in 20 to 25% of adenomas, especially those larger than 5 cm, and malignant transformation into liver cancer happens in up to 7% of cases at referral centers.
FNH, by contrast, has essentially no documented risk of becoming cancerous, and hemorrhage or rupture is so rare it may not truly occur outside of patients on oral contraceptives. The two lesions also differ structurally. FNH is organized around portal tracts, the liver’s normal plumbing, while adenomas are fed by isolated arteries without those normal support structures. On the glutamine synthetase stain, FNH shows the broad map-like pattern described above, while adenomas are either diffusely positive (in one specific subtype) or mostly negative.
These differences matter because management diverges sharply. Adenomas often require monitoring with repeat imaging, sometimes surgical removal, and strict avoidance of estrogen-containing contraceptives. FNH rarely requires any intervention at all.
What Happens After Diagnosis
Once FNH is confidently identified, most people need no treatment. The lesion is not precancerous, it rarely grows significantly, and complications are extraordinarily uncommon. Many doctors will recommend one follow-up imaging study six to twelve months after the initial discovery to confirm the lesion is stable, then no further monitoring.
For women taking estrogen-based oral contraceptives, the conversation is more nuanced. Because estrogen exposure is associated with larger nodules and the handful of reported complications have occurred in contraceptive users, stopping or switching to a non-estrogen method is a reasonable consideration, particularly with larger lesions. Weight management can also help reduce the body’s circulating estrogen.
Surgery is reserved for the small number of patients who develop persistent symptoms from a large FNH pressing on surrounding structures, or for cases where the diagnosis remains genuinely uncertain despite advanced imaging and the possibility of an adenoma cannot be excluded. For the overwhelming majority of people, FNH is a benign finding that requires nothing more than reassurance.